Study Title: Assessment of Oral Cannabidiol on Symptoms of Anxiety
You are invited to participate in a research study to evaluate the effectiveness of Cannabidiol (CBD) to provide relief of stress, and Anxiety in Healthy Adults. This study is being sponsored by Panacea Life Sciences and led by James W. Baumgartner, Ph.D.
We ask that you read this form and ask any questions prior to agreeing to participate in this study. If you consent to enter the study and agree to participate, please indicate agreement in the sections below and enter in contact information.
Background and Purpose
Panacea Life Sciences is a Limited Liability Company that manufacture dietary supplements. Panacea conducts scientific studies, including open-label clinical studies to assess health benefits of dietary supplements. In this study, Panacea is recruiting health adults to participate in assessing oral cannabidiol will improve perceived stress and anxiety in healthy adults. The majority of subjects enrolled will not be currently taking medications, however those on current medications are allowed to participate. Participants will receive Panacea cannabidiol products at a dose of 50-60 mg CBD per day. Participants will be asked to complete an anxiety assessment questionnaire prior to enrollment and after 2 weeks of CBD supplementation.
The objective of the study is to:
1. Evaluate the efficacy of test products as options for management of people who experience stress or have anxiety.
2. Evaluate two different dosage forms for the ability to alleviate anxiety.
3. Assess palatability, ease of administration, and potential for side effects associated with administration of the test products.
Cannabidiol has been reported to have a potential benefit for treating a wide range of conditions (e.g. osteoarthritis, anxiety, neurologic and endocrine disease and drug-resistant infections). We are evaluating this product in stages to determine how best it can be utilized to improve the quality of life of patients with the aforementioned conditions as a sole agent or as an adjunct to more
traditional therapies.
Study Procedures:
Assessment: Upon consenting to participate in the study, subjects will be asked to complete a questionnaire to assess current state of stress or anxiety. The purpose of the questionnaire is to establish a baseline level of stress so that CBD supplementation effects may be measured.
Study Supplement: Consenting subjects will take the provided FAST product, 25 mg CBD per tablet, twice daily; or a 20 mg CBD full spectrum hemp oil soft gel, three times daily. Preference for the study material is indicated at the end of this form.
Ongoing Assessment: At 2 weeks participants will be asked to complete the stress and anxiety assessment. At the end of the study subjects will receive an additional bottle of product corresponding to what was taken during the study as compensation and appreciation for participation in the trial. Participants should continue on any medication or therapies, but ask that these be reported in the surveys.
Risks of study participation: During the course of the study subjects may experience side effects from the CBD supplement including diarrhea, vomiting, or lethargy. While other undesirable side effects may occur, the dose of CBD used in this study is well below doses used in other studies that established safe, tolerable doses of the product. As a consequence, should any of the aforementioned side effects occur, or if subjects have increased feelings of anxiety or depression, they should immediately stop taking the CBD product, contact their primary health provider as well as contact Panacea Life Sciences as soon as conv